MNKD - MannKind Corporation

-

$undefined

N/A

(N/A)

MannKind Corporation NasdaqGM:MNKD MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Location: 1 Casper Street, Danbury, CT, 06810, United States | Website: https://www.mannkindcorp.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.218B

Cash

188M

Avg Qtr Burn

N/A

Short % of Float

8.67%

Insider Ownership

1.86%

Institutional Own.

58.65%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Afrezza® (insulin human) Inhalation Powder Details
Diabetes, Type 1 diabetes, Type 2 diabetes

Approved

Quarterly sales

Approved

Quarterly sales

Afrezza® (insulin human) Inhalation Powder Details
Type 1 diabetes, Diabetes, Type 2 diabetes

sNDA

Submission

Clofazimine inhalation suspension (MNKD 101) Details
Nontuberculous mycobacterial lung disease, Lung disease

Phase 3

Update

MNKD 201 (nintedanib DPI) Details
Lung disease, Idiopathic pulmonary fibrosis

Phase 1

Update